Please do not leave this page until complete. This can take a few moments.
Biohaven Pharmaceuticals said Tuesday that a clinical trial for its experimental drug to treat a rare, fatal brain disease has reached full enrollment.
The New Haven company said it completed the enrollment ahead of schedule despite challenges from COVID-19. Results are expected by the end of 2021.
The trial, called M-STAR, is testing the safety and efficacy of Biohaven’s drug verdiperstat for patients with Multiple System Atrophy (MSA), a progressive and fatal neurodegenerative disease.
The disease afflicts around 50,000 people in the United States and Europe. Patients usually die within six to 10 years of diagnosis, according to Biohaven.
Around 300 MSA patients in roughly 50 sites in the United States and Europe are taking part in the 48-week study, Biohaven said.
Biohaven licensed verdiperstat, an MPO inhibitor, from drug giant AstraZeneca in 2018. It works by targeting sources of brain inflammation that can contribute to brain cell death in neurodegenerative diseases.
Biohaven is also testing the drug for the treatment of ALS (amyotrophic lateral sclerosis) as part of a unique clinical trial being led by Massachusetts General Hospital.
Contact Natalie Missakian at news@newhavenbiz.com
This special edition informs and connects businesses with nonprofit organizations that are aligned with what they care about. Each nonprofit profile provides a crisp snapshot of the organization’s mission, goals, area of service, giving and volunteer opportunities and board leadership.
Learn moreHartford Business Journal provides the top coverage of news, trends, data, politics and personalities of the area’s business community. Get the news and information you need from the award-winning writers at HBJ. Don’t miss out - subscribe today.
SubscribeDelivering Vital Marketplace Content and Context to Senior Decision Makers Throughout Greater Hartford and the State ... All Year Long!
Read HereThis special edition informs and connects businesses with nonprofit organizations that are aligned with what they care about. Each nonprofit profile provides a crisp snapshot of the organization’s mission, goals, area of service, giving and volunteer opportunities and board leadership.
Hartford Business Journal provides the top coverage of news, trends, data, politics and personalities of the area’s business community. Get the news and information you need from the award-winning writers at HBJ. Don’t miss out - subscribe today.
Delivering Vital Marketplace Content and Context to Senior Decision Makers Throughout Greater Hartford and the State ... All Year Long!
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
This website uses cookies to ensure you get the best experience on our website. Our privacy policy
To ensure the best experience on our website, articles cannot be read without allowing cookies. Please allow cookies to continue reading. Our privacy policy
0 Comments